In murine and human lung cancer cell lines and genetically engineered mouse lung cancer models, Vorinostat reduced cancer cell growth, cyclin D1 and cyclin E expressions, but increased p27 expression, histone acetylation and apoptosis [41]. The gene discussed is CCND1; the disease is lung carcinoma.